Enhancing Value-Based Decision-Making With Cytogenetic Findings

Web Exclusives
Download Newsletter

Over the past 20 years, research in multiple myeloma (MM) has delineated the molecular and genetic mechanisms of the disease. These findings have resulted in clinically important advances: the development of novel, molecularly targeted drugs, such as bortezomib and lenalidomide, and the use of cytogenetic testing to stratify risk.1-4 We now know that specific genetic mutations confer an especially unfavorable prognosis in MM; for example, deletion at the short arm of chromosome 17 [del(17p)] and translocations involving chromosomes 4, 14, and 16 [t(4;14) and t(14;16)].2,3 Clinicians test for these abnormalities with 2 core cytogenetic testing modalities: conventional metaphase karyotyping and fluorescence in situ hybridization (FISH).5

Last modified: March 7, 2019
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology